July 2026 – schizophrenia

Jul 31 2026

Uncategorized

MapLight CEO on what investors missed in the biotech’s schizophrenia data – BioPharma Dive

by Clinical Editor

No Comments

MapLight CEO on what investors missed in the biotech’s schizophrenia data BioPharma Dive

Jul 31 2026

Uncategorized

Genetic deletions may help explain differences in schizophrenia severity

by Clinical Editor

No Comments

Schizophrenia affects approximately 23 million people worldwide, with onset usually occurring during a person’s late adolescence or 20s. Impairments associated with schizophrenia include …

Jul 30 2026

Uncategorized

MapLight CEO on what investors missed in the biotech’s schizophrenia data

by Clinical Editor

No Comments

Though positive, mid-stage study results erased about two-thirds of the biotech’s market value this week. But Christopher Kroeger sees MapLight’s drug as competitive based on the “totality of data.” …

Jul 30 2026

Uncategorized

Diagnosed with schizophrenia — what should I do now?

by Clinical Editor

No Comments

Learn about the impact of schizophrenia on daily life, as well as treatment options and lifestyle changes that can help you or a loved one manage the symptoms.

Jul 29 2026

Uncategorized

MapLight dives despite positive data for schizophrenia drug

by Clinical Editor

No Comments

Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers’ Cobenfy.

Jul 29 2026

Uncategorized

MapLight’s schizophrenia drug fails once-daily test, shares plunge

by Clinical Editor

No Comments

July 27 (Reuters) – MapLight Therapeutics said on Monday its schizophrenia drug failed to show statistically significant symptom improvement in the once-daily dosing arm of a mid-stage trial, sending …

Jul 28 2026

Uncategorized

MapLight Therapeutics stock falls despite schizophrenia drug meeting main trial goal

by Clinical Editor

No Comments

MapLight Therapeutics Inc. MPLT stock is trading lower on Monday after the company reported topline data from its Phase 2 ZEPHYR trial of ML-007C-MA, an oral M1/M4 muscarinic agonist (betovumeline)...

Jul 28 2026

Uncategorized

MapLight Therapeutics’ Lead Candidate Falls Meaningfully Short In Schizophrenia

by Clinical Editor

No Comments

MapLight Therapeutics faces significant setbacks after underwhelming Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia. Click for this MPLT stock update.

Jul 27 2026

Uncategorized